NTI 2.04% 5.0¢ neurotech international limited

Ann: Phase II/III ASD Trial Successfully Meets Primary Endpoint, page-7

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,540 Posts.
    lightbulb Created with Sketch. 511
    What does the company need to do now to submit for FDA approval?

    Just toxicology studies? Or another clinical trial?
 
watchlist Created with Sketch. Add NTI (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.